M1 Kliniken AG Enhances Beauty Business with Strategic Refocus

M1 Kliniken AG reported a 37.6% increase in EBIT for its Beauty segment, reaching EUR 9.2 million. The strategic refocus was achieved by selling HAEMATO Pharm GmbH while concentrating on high-margin aesthetic medicine. First-quarter revenue rose by 5.7% to EUR 27.1 million. The EBIT margin improved to 33.9%, reinforcing the segment as a growth catalyst.

The sale impacted group figures, with overall revenue at EUR 46.8 million, down from the previous year's EUR 92.7 million, and group EBIT at EUR 5 million. A planned exit from trading explained the drop, with revenue at EUR 19.7 million compared to EUR 67.2 million the prior year.

Looking forward, M1 Kliniken AG aims to extend its clinic network domestically and internationally, targeting EUR 200-300 million in Beauty segment revenue by 2029, maintaining a minimum 20% EBIT margin.